Literature DB >> 24561735

Lumen enlargement of the coronary segments located distal to chronic total occlusions successfully treated with drug-eluting stents at follow-up.

Josep Gomez-Lara1, Luis Teruel, Silvia Homs, José Luis Ferreiro, Rafael Romaguera, Gerard Roura, Guillermo Sánchez-Elvira, Francesc Jara, Salvatore Brugaletta, Joan-Antoni Gomez-Hospital, Angel Cequier.   

Abstract

AIMS: Chronic total occlusions (CTO) are the final stage of atherosclerosis. Occluded coronary arteries have large plaque burden and negative remodelling. The aim of this study was to assess lumen and vessel changes of segments located distal to successfully recanalised CTO. METHODS AND
RESULTS: Ninety-one CTO treated with drug-eluting stents underwent quantitative coronary angiography (QCA) at baseline and at 12-18 months; 31 underwent serial intravascular ultrasound (IVUS) imaging. Angiographic changes were assessed with QCA as differences in minimal, mean and maximal lumen diameter (MinLD, MeanLD and MaxLD, respectively). Vessel changes were assessed with IVUS as changes in plaque and vessel volume. At follow-up, angiographic MinLD increased 23.9% (from 0.88±0.32 to 1.09±0.35 mm; p<0.01), MeanLD 16.4% (from 1.59±0.44 to 1.85±0.45 mm; p<0.01) and MaxLD 11.7% (from 2.39±0.67 to 2.67±0.70 mm; p<0.01). Lumen enlargement was greater in non-restenotic lesions, small lumen area at the end of the index procedure and low LDL-cholesterol levels during the study. By IVUS, lumen volume increased 26.9% (from 108.1±89.2 to 137.3±115.3 mm3; p<0.01), vessel volume increased 12.1% (from 207.1±170.2 to 232.2±196.0 mm3; p<0.01) and plaque volume tended to decrease 3.9% (from 98.9±88.7 to 94.9±89.3 mm3; p=0.07). Small lumen at baseline was related to greater lumen enlargement.
CONCLUSIONS: Segments distal to recanalised CTO showed a notable lumen and vessel enlargement with a trend toward mild plaque regression. Low LDL-cholesterol levels increase lumen enlargement.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24561735     DOI: 10.4244/EIJV9I10A199

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  4 in total

1.  Circulatory disturbance of the cochlear spiral modiolar artery in a type 2 diabetic mouse model.

Authors:  Young Joon Seo; Dae Bo Shim; Arazu Sharif; Zeke Samson; Ryu Takechi; Daniel Brown
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-09-09

2.  Recovery of Absolute Coronary Blood Flow and Microvascular Resistance After Chronic Total Occlusion Percutaneous Coronary Intervention: An Exploratory Study.

Authors:  Daniëlle C J Keulards; Grigoris V Karamasis; Osama Alsanjari; Jesse P A Demandt; Marcel Van't Veer; Jo M Zelis; Simon A Dello; Mohamed El Farissi; Klio Konstantinou; Kare H Tang; Paul A Kelly; Thomas R Keeble; Nico H J Pijls; John R Davies; Koen Teeuwen
Journal:  J Am Heart Assoc       Date:  2020-04-22       Impact factor: 5.501

3.  Clinical Outcomes of Drug-Coated Balloon Treatment After Successful Revascularization of de novo Chronic Total Occlusions.

Authors:  Eun Jung Jun; Eun-Seok Shin; Eu-Vin Teoh; Youngjune Bhak; Song Lin Yuan; Chong-Mow Chu; Scot Garg; Houng Bang Liew
Journal:  Front Cardiovasc Med       Date:  2022-04-13

4.  Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study.

Authors:  Javier Escaned; Carlos Collet; Nicola Ryan; Giovanni Luigi De Maria; Simon Walsh; Manel Sabate; Justin Davies; Maciej Lesiak; Raul Moreno; Ignacio Cruz-Gonzalez; Stephan P Hoole; Nick Ej West; J J Piek; Azfar Zaman; Farzin Fath-Ordoubadi; Rodney H Stables; Clare Appleby; Nicolas van Mieghem; Robert Jm van Geuns; Neal Uren; Javier Zueco; Pawel Buszman; Andres Iñiguez; Javier Goicolea; David Hildick-Smith; Andrzej Ochala; Dariusz Dudek; Colm Hanratty; Rafael Cavalcante; Arie Pieter Kappetein; David P Taggart; Gerrit-Anne van Es; Marie-Angèle Morel; Ton de Vries; Yoshinobu Onuma; Vasim Farooq; Patrick W Serruys; Adrian P Banning
Journal:  Eur Heart J       Date:  2017-11-07       Impact factor: 29.983

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.